Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy

Human Molecular Genetics

Volumn 19, Issue 10, 2010, Pages 2005-2014

  Fourcade, Stéphane ^a,b   Ruiz, Montserrat ^a,b   Guilera, Cristina ^a,b   Hahnen, Eric ^c,d   Brichta, Lars ^c,m   Naudi, Alba ^e   Portero Otín, Manuel ^e   Dacremont, Georges ^f   Cartier, Nathalie ^g   Wanders, Ronald ^h   Kemp, Stephan ^h   Mandel, Jean Louis ^i,j,k   Wirth, Brunhilde ^c   Pamplona, Reinald ^e   Aubourg, Patrick ^g   Pujol, Aurora ^a,b,l  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e UNIVERSITY OF LLEIDA   (Spain)

^f GHENT UNIVERSITY   (Belgium)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁱ l'alimentation et l'Environnement   (France)

^j INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^k INSTITUT CLINIQUE DE LA SOURIS   (France)

^l INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^m ROCKEFELLER UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; PROTEIN ABCD2; REACTIVE OXYGEN METABOLITE; RNA; UNCLASSIFIED DRUG; VALPROIC ACID; VERY LONG CHAIN FATTY ACID;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADRENOLEUKODYSTROPHY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN SLICE; CHILD; CHILDHOOD ADRENOLEUKODYSTROPHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; FATTY ACID METABOLISM; FIBROBLAST CULTURE; GENE OVEREXPRESSION; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SCHOOL CHILD;

ACETYLTRANSFERASES; ADOLESCENT; ADRENOLEUKODYSTROPHY; ANIMALS; ANTIOXIDANTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL MARKERS; CHILD; FATTY ACIDS; FIBROBLASTS; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; OXIDATIVE STRESS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SPINAL CORD; VALPROIC ACID;

EID: 77952508899     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq082     Document Type: Article

References (63)

1. Moser, H., Smith, K.D., Watkins, P.A., Powers, J. and Moser, A.B. (2001) X-linked adrenoleukodystrophy. In Scriver, C. (ed.), The Metabolic and Molecular Bases of Inherited Disease, 8th edn. McGraw-Hill, New York, Vol. II, pp. 3257-3301.
2. Valianpour, F., Selhorst, J.J., van Lint, L.E., van Gennip, A.H., Wanders, R.J. and Kemp, S. (2003) Analysis of very long-chain fatty acids using electrospray ionization mass spectrometry. Mol. Genet. Metab., 79, 189-196.
3. Mosser, J., Douar, A.M., Sarde, C.O., Kioschis, P., Feil, R., Moser, H., Poustka, A.M., Mandel, J.L. and Aubourg, P. (1993) Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature, 361, 726-730.
4. Hettema, E.H., van Roermund, C.W., Distel, B., van den Berg, M., Vilela, C., Rodrigues-Pousada, C., Wanders, R.J. and Tabak, H.F. (1996) The ABC transporter proteins Pat1 and Pat2 are required for import of long-chain fatty acids into peroxisomes of Saccharomyces cerevisiae. EMBO J., 15, 3813-3822.
5. Shani, N., Watkins, P.A. and Valle, D. (1995) PXA1, a possible Saccharomyces cerevisiae ortholog of the human adrenoleukodystrophy gene. Proc. Natl Acad. Sci. USA, 92, 6012-6016.
6. van Roermund, C.W., Visser, W.F., Ijlst, L., van Cruchten, A., Boek, M., Kulik, W., Waterham, H.R. and Wanders, R.J. (2008) The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters. FASEB J., 22, 4201-4208.
7. Aubourg, P., Adamsbaum, C., Lavallard-Rousseau, M.C., Rocchiccioli, F., Cartier, N., Jambaque, I., Jakobezak, C., Lemaitre, A., Boureau, F., Wolf, C. et al. (1993) A two-year trial of oleic and erucic acids ('Lorenzo's oil') as treatment for adrenomyeloneuropathy. N. Engl. J. Med., 329, 745-752.
8. Shapiro, E., Krivit, W., Lockman, L., Jambaque, I., Peters, C., Cowan, M., Harris, R., Blanche, S., Bordigoni, P., Loes, D. et al. (2000) Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet, 356, 713-718.
9. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L. et al. (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science, 326, 818-823.
10. Saunthararajah, Y., Hillery, C.A., Lavelle, D., Molokie, R., Dorn, L., Bressler, L., Gavazova, S., Chen, Y.H., Hoffman, R. and DeSimone, J. (2003) Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood, 102, 3865-3870.
11. Khurana, T.S. and Davies, K.E. (2003) Pharmacological strategies for muscular dystrophy. Nat. Rev. Drug Discov., 2, 379-390.
12. Brichta, L., Hofmann, Y., Hahnen, E., Siebzehnrubl, F.A., Raschke, H., Blumcke, I., Eyupoglu, I.Y. and Wirth, B. (2003) Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum. Mol. Genet., 12, 2481-2489.
13. Hahnen, E., Eyupoglu, I.Y., Brichta, L., Haastert, K., Trankle, C., Siebzehnrubl, F.A., Riessland, M., Holker, I., Claus, P., Romstock, J. et al. (2006) In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J. Neurochem., 98, 193-202.
14. Vasiliou, V., Vasiliou, K. and Nebert, D.W. (2009) Human ATP-binding cassette (ABC) transporter family. Hum. Genomics, 3, 281-290.
15. Lombard-Platet, G., Savary, S., Sarde, C.O., Mandel, J.L. and Chimini, G. (1996) A close relative of the adrenoleukodystrophy (ALD) gene codes for a peroxisomal protein with a specific expression pattern. Proc. Natl Acad. Sci. USA, 93, 1265-1269.
16. Schluter, A., Fourcade, S., Domenech-Estevez, E., Gabaldon, T., Huerta-Cepas, J., Berthommier, G., Ripp, R., Wanders, R.J., Poch, O. and Pujol, A. (2007) PeroxisomeDB: a database for the peroxisomal proteome, functional genomics and disease. Nucleic Acids Res., 35, D815-D822.
17. Kemp, S., Wei, H.M., Lu, J.F., Braiterman, L.T., McGuinness, M.C., Moser, A.B., Watkins, P.A. and Smith, K.D. (1998) Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nat. Med., 4, 1261-1268.
18. Netik, A., Forss-Petter, S., Holzinger, A., Molzer, B., Unterrainer, G. and Berger, J. (1999) Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy. Hum. Mol. Genet., 8, 907-913.
19. Fourcade, S., Ruiz, M., Camps, C., Schluter, A., Houten, S.M., Mooyer, P.A., Pampols, T., Dacremont, G., Wanders, R.J., Giros, M. et al. (2009) A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis. Am. J. Physiol. Endocrinol. Metab., 296, E211-E221.
20. Pujol, A., Ferrer, I., Camps, C., Metzger, E., Hindelang, C., Callizot, N., Ruiz, M., Pampols, T., Giros, M. and Mandel, J.L. (2004) Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Hum. Mol. Genet., 13, 2997-3006.
21. Pujol, A., Hindelang, C., Callizot, N., Bartsch, U., Schachner, M. and Mandel, J.L. (2002) Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum. Mol. Genet., 11, 499-505.
22. Gondcaille, C., Depreter, M., Fourcade, S., Lecca, M.R., Leclercq, S., Martin, P.G., Pineau, T., Cadepond, F., ElEtr, M., Bertrand, N. et al. (2005) Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator. J. Cell Biol., 169, 93-104.
23. Kemp, S. and Wanders, R.J. (2007) X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment. Mol. Genet. Metab., 90, 268-276.
24. Kernochan, L.E., Russo, M.L., Woodling, N.S., Huynh, T.N., Avila, A.M., Fischbeck, K.H. and Sumner, C.J. (2005) The role of histone acetylation in SMN gene expression. Hum. Mol. Genet., 14, 1171-1182.
25. Labiner, D.M. (2002) DP-VPA D-Pharm. Curr. Opin. Investig. Drugs, 3, 921-923.
26. Leng, Y. and Chuang, D.M. (2006) Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J. Neurosci., 26, 7502-7512.
27. van Bergeijk, J., Haastert, K., Grothe, C. and Claus, P. (2006) Valproic acid promotes neurite outgrowth in PC12 cells independent from regulation of the survival of motoneuron protein. Chem. Biol. Drug. Des., 67, 244-247.
28. Swoboda, K.J., Scott, C.B., Reyna, S.P., Prior, T.W., LaSalle, B., Sorenson, S.L., Wood, J., Acsadi, G., Crawford, T.O., Kissel, J.T. et al. (2009) Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One, 4, e5268.
29. Tsai, L.K., Yang, C.C., Hwu, W.L. and Li, H. (2007) Valproic acid treatment in six patients with spinal muscular atrophy. Eur. J. Neurol., 14, e8-e9.
30. Weihl, C.C., Connolly, A.M. and Pestronk, A. (2006) Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology, 67, 500-501.
31. Fourcade, S., Lopez-Erauskin, J., Galino, J., Duval, C., Naudi, A., Jove, M., Kemp, S., Villarroya, F., Ferrer, I., Pamplona, R. et al. (2008) Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum. Mol. Genet., 17, 1762-1773.
32. Braiterman, L.T., Zheng, S., Watkins, P.A., Geraghty, M.T., Johnson, G., McGuinness, M.C., Moser, A.B. and Smith, K.D. (1998) Suppression of peroxisomal membrane protein defects by peroxisomal ATP binding cassette (ABC) proteins. Hum. Mol. Genet., 7, 239-247.
33. Asheuer, M., Bieche, I., Laurendeau, I., Moser, A., Hainque, B., Vidaud, M. and Aubourg, P. (2005) Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy. Hum. Mol. Genet., 14, 1293-1303.
34. Lagace, D.C. and Nachtigal, M.W. (2004) Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis. J. Biol. Chem., 279, 18851-18860.
35. Eikel, D., Hoffmann, K., Zoll, K., Lampen, A. and Nau, H. (2006) S-2-Pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides. Drug. Metab. Dispos., 34, 612-620.
36. Venkataramani, V., Rossner, C., Iffland, L., Schweyer, S., Tamboli, I., Walter, J., Wirths, O. and Bayer, T.A. The histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the Alzheimer amyloid precursor protein. J. Biol. Chem., 2010; Epub ahead of print February 9.
37. Powers, J.M., Pei, Z., Heinzer, A.K., Deering, R., Moser, A.B., Moser, H.W., Watkins, P.A. and Smith, K.D. (2005) Adreno-leukodystrophy: oxidative stress of mice and men. J. Neuropathol. Exp. Neurol., 64, 1067-1079.
38. Uto, T., Contreras, M.A., Gilg, A.G. and Singh, I. (2008) Oxidative imbalance in nonstimulated X-adrenoleukodystrophy-derived lymphoblasts. Dev. Neurosci., 30, 410-418.
39. Vargas, C.R., Wajner, M., Sirtori, L.R., Goulart, L., Chiochetta, M., Coelho, D., Latini, A., Llesuy, S., Bello-Klein, A., Giugliani, R. et al. (2004) Evidence that oxidative stress is increased in patients with X-linked adrenoleukodystrophy. Biochim. Biophys. Acta, 1688, 26-32.
40. Requena, J.R., Chao, C.C., Levine, R.L. and Stadtman, E.R. (2001) Glutamic and aminoadipic semialdehydes are the main carbonyl products of metal-catalyzed oxidation of proteins. Proc. Natl Acad. Sci. USA, 98, 69-74.
41. Thorpe, S.R. and Baynes, J.W. (2003) Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids, 25, 275-281.
42. Fourcade, S., Savary, S., Gondcaille, C., Berger, J., Netik, A., Cadepond, F., El Etr, M., Molzer, B. and Bugaut, M. (2003) Thyroid hormone induction of the adrenoleukodystrophy-related gene (ABCD2). Mol. Pharmacol., 63, 1296-1303.
43. Sharp, P., Johnson, D. and Poulos, A. (1991) Molecular species of phosphatidylcholine containing very long chain fatty acids in human brain: enrichment in X-linked adrenoleukodystrophy brain and diseases of peroxisome biogenesis brain. J. Neurochem., 56, 30-37.
44. Wieser, H.G. (1991) Comparison of valproate concentrations in human plasma, CSF and brain tissue after administration of different formulations of valproate or valpromide. Epilepsy Res., 9, 154-159.
45. Hauke, J., Riessland, M., Lunke, S., Eyupoglu, I.Y., Blumcke, I., El-Osta, A., Wirth, B. and Hahnen, E. (2009) Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Hum. Mol. Genet., 18, 304-317.
46. Stoppini, L., Buchs, P.A. and Muller, D. (1991) A simple method for organotypic cultures of nervous tissue. J. Neurosci. Methods, 37, 173-182.
47. Kortenhorst, M.S., Zahurak, M., Shabbeer, S., Kachhap, S., Galloway, N., Parmigiani, G., Verheul, H.M. and Carducci, M.A. (2008) A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors. Clin. Cancer Res., 14, 6886-6894.
48. Jakobsson, A., Westerberg, R. and Jacobsson, A. (2006) Fatty acid elongases in mammals: their regulation and roles in metabolism. Prog. Lipid. Res., 45, 237-249.
49. Leonard, A.E., Pereira, S.L., Sprecher, H. and Huang, Y.S. (2004) Elongation of long-chain fatty acids. Prog. Lipid. Res., 43, 36-54.
50. Agbaga, M.P., Brush, R.S., Mandal, M.N., Henry, K., Elliott, M.H. and Anderson, R.E. (2008) Role of Stargardt-3 macular dystrophy protein (ELOVL4) in the biosynthesis of very long chain fatty acids. Proc. Natl Acad. Sci. USA, 105, 12843-12848.
51. Vasireddy, V., Uchida, Y., Salem, N. Jr, Kim, S.Y., Mandal, M.N., Reddy, G.B., Bodepudi, R., Alderson, N.L., Brown, J.C., Hama, H. et al. (2007) Loss of functional ELOVL4 depletes very long-chain fatty acids (> or = C28) and the unique omega-O-acylceramides in skin leading to neonatal death. Hum. Mol. Genet., 16, 471-482.
52. Brolinson, A., Fourcade, S., Jakobsson, A., Pujol, A. and Jacobsson, A. (2008) Steroid hormones control circadian Elovl3 expression in mouse liver. Endocrinology, 149, 3158-3166.
53. Rothstein, J.D. (2009) Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol., 65 (Suppl. 1), S3-S9.
54. Zhou, C., Huang, Y. and Przedborski, S. (2008) Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann. N. Y. Acad. Sci., 1147, 93-104.
55. Deon, M., Wajner, M., Sirtori, L.R., Fitarelli, D., Coelho, D.M., Sitta, A., Barschak, A.G., Ferreira, G.C., Haeser, A., Giugliani, R. et al. (2006) The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy. J. Neurol. Sci., 247, 157-164.
56. Kemp, S., Valianpour, F., Denis, S., Ofman, R., Sanders, R.J., Mooyer, P., Barth, P.G. and Wanders, R.J. (2005) Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy. Mol. Genet. Metab., 84, 144-151.
57. Bachmann, R.F., Wang, Y., Yuan, P., Zhou, R., Li, X., Alesci, S., Du, J. and Manji, H.K. (2009) Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int. J. Neuropsychopharmacol., 12, 805-822.
58. Cui, J., Shao, L., Young, L.T. and Wang, J.F. (2007) Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience, 144, 1447-1453.
59. Lai, J.S., Zhao, C., Warsh, J.J. and Li, P.P. (2006) Cytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur. J. Pharmacol., 539, 18-26.
60. Chang, T.K. and Abbott, F.S. (2006) Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity. Drug Metab. Rev., 38, 627-639.
61. Lheureux, P.E. and Hantson, P. (2009) Carnitine in the treatment of valproic acid-induced toxicity. Clin. Toxicol. (Phila.), 47, 101-111.
62. ten Brink, H., Jacobs, C. and Bickelhaupt, F. (1989) Synthesis and applications of isotopically labeled compounds. In Baillie, T. and Jones, J.R. (eds), Synthesis and Applications of Isotopically Labelled Compounds. Elsevier, Amsterdam, pp. 723-726.
63. Eyüpoglu, I.Y., Hahnen, E., Buslei, R., Siebzehnrübl, F.A., Savaskan, N.E., Lüders, M., Tränkle, C., Wick, W., Weller, M., Fahlbusch, R. et al. (2005) Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J. Neurochem., 93, 992-999.